All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The impact of Minimal Residual Disease (MRD) on the outcomes of pediatric Acute Myeloid Leukemia (AML) patients who underwent Allogenic Stem Cell Transplantation (allo-SCT) is not very clear, particularly in the Haploidentical SCT (halpo-SCT) setting.
In a Letter to the Editor of American Journal of Hematology on 20th September 2017, Ying-Jun Chang et al. from the Peking University People’s Hospital & Peking University Institute of Hematology, Beijing, China, discussed results of their study which evaluated the effects of pre- and post- transplantation MRD as determined using Multiparameter Flow Cytometry (MFC) on the outcomes of pediatric AML patients.
Overall, 161 pediatric AML patients who underwent allo-SCT via HLA-matched Sibling Donor (MSDT) or halpo-SCT were analyzed in this study. MRD was evaluated prior to allo-SCT and between 30–180 days after transplantation using MFC.
Patients were classified into four groups depending on their pre-MRD status, MRD negative (MRDneg) or MRD positive (MRDpos), and the source of transplant, MSDT or halpo-SCT. These groups included patients with pre-MRDneg status who received MSDT (group A [n = 6]), pre-MRDpos status who received MSDT (group B [n = 6]), pre-MRDneg status who received Haplo-SCT (group C [n = 115]) and pre-MRDpos status who received haplo-HSCT (group D [n = 34]).
In summary, positive pre-MRD status with halpo-SCT was associated with a lower CIR and a superior LFS and OS compared to patients who underwent MSDT. Key limitations of the study included its retrospective, single center setting with a small number of patients receiving MSDT, and the non-unform sensitivity of MFC-based MRD detection.
The authors concluded by suggesting that “halpo-SCT may have a strong Graft Versus Leukemia (GVL [reduction of relapse]) effect for pre-MRD positive AML patients in both adult and pediatric” AML patients.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox